Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib

Proteinuria is one of the most frequently reported adverse events leading to the discontinuation of lenvatinib treatment in patients with advanced hepatocellular carcinoma (HCC). However, there are no reports regarding the risk factors of proteinuria in patients with HCC or patients receiving lenvatinib. We retrospectively reviewed the medical records of patients with HCC receiving lenvatinib at the Kobe City Medical Center General Hospital between April 2018 and December 2020. The severity of proteinuria was graded based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A multivariate Cox proportional hazards model was employed to identify the risk factors of developing grade 60 mL/min/1.73 m(2) at baseline. Grades 1, 2, and 3 proteinuria were observed in 15 (40.5%), 10 (27.0%), and 2 (5.4%) patients, respectively, during lenvatinib treatment. The median value of eGFR was significantly lower in patients who developed grade 60 mL/min/1.73 m(2) at baseline (HR, 4.49; 95% CI, 1.32-16.07; p = 0.017) were significantly associated with developing grade >= 2 proteinuria. These patients should be monitored carefully, and our preliminary data should be confirmed by further studies.

Automated summary

Proteinuria is a common adverse event in patients with hepatocellular carcinoma (HCC) receiving lenvatinib treatment. This study retrospectively reviewed the medical records of HCC patients receiving lenvatinib and identified lower baseline estimated glomerular filtration rate (eGFR) as a risk factor for developing proteinuria.